ClinicalTrials.gg
CompletedNCT00370318Updated Mar 23, 2017

Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate and Standard Infant Vaccines

A Phase 3 interventional study of 10 valent pneumococcal conjugate vaccine and Infanrix Hexa in Infections, Rotavirus, sponsored by GlaxoSmithKline. Completed at 10 sites in Czech Republic. Open to participants aged 9 Weeks to 16 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-23.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
9 Weeks to 16 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 19 studies testing RIX4414 vaccine in Rotavirus Infections — none open to participants now, none under way, none of them phase 3. RIX4414 vaccine · Rotavirus Infections.

Enrollment
12th of 19
400 · median 472
Started
2006
the only one that year
Phase 3
9 of 19
none open now
Registered
4th of 19
by date
Lead sponsor
17 of 19
GlaxoSmithKline

Among the 19 studies testing RIX4414 vaccine in Rotavirus Infections, this one is the 12th largest by enrollment, is the only one that started in 2006, is one of 9 in phase 3, and was the 4th registered.

Rotavirus Infections

104 studies on the registry are indexed under Rotavirus Infections; 3 are open to participants now.

Browse Rotavirus Infections studies →

Open to participants now

None of the 19 studies testing RIX4414 vaccine in Rotavirus Infections is open now. The open studies under Rotavirus Infections, anywhere →

About RIX4414 vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 3 Rotavirus Infections studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 9 Weeks to 16 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing RIX4414 vaccine in Rotavirus Infections as a file.
02

Study summary

The purpose of this trial is to assess if the rate of febrile reactions following the co-administration of pneumococcal conjugate vaccines with standard infant vaccines is lowered when paracetamol is given prophylactically.

Read the detailed description

2 groups (200 per group); control group receives no prophylactic antipyretic treatment.

03

Conditions studied

  • Infections, Rotavirus

Keywords

  • Pneumococcal Disease
04

Who can participate

Ages eligible
9 Weeks to 16 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy children 9-16 weeks old and born after a gestation of at least 36 weeks.

Exclusion criteria

Exclusion Criteria:

  • Body weight \< 4.5 kg
  • Children having received or planning to receive any or non-registered products, vaccines not foreseen in the protocol, and immune modifying drugs
  • Children with any disease that affects the immune system or gastro-intestinal tract
  • Children with a history of seizures, allergic disease, or disease(s) covered by the vaccines
  • Children with to paracetamol treatment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Occurrence of fever > or = to 38°C (rectal temperature)

Secondary outcomes

  1. Safety, reactogenicity and immunogenicity pre and post-vaccination

07

Study locations

10 sites
  • GSK Investigational Site
    Brno, 628 00, Czech Republic
  • GSK Investigational Site
    Hradec Kralove, 500 01, Czech Republic
  • GSK Investigational Site
    Jindrichuv Hradec, 377 01, Czech Republic
  • GSK Investigational Site
    Nachod, 547 01, Czech Republic
  • GSK Investigational Site
    Ostrava, 728 92, Czech Republic
  • GSK Investigational Site
    Pardubice, 532 03, Czech Republic
  • GSK Investigational Site
    Praha 5, 150 00, Czech Republic
  • GSK Investigational Site
    Praha 6, 160 00, Czech Republic
  • GSK Investigational Site
    Praha 9, 190 00, Czech Republic
  • GSK Investigational Site
    Znojmo, 669 00, Czech Republic
08

References and documents

Publications

  • Prymula R, Siegrist CA, Chlibek R, Zemlickova H, Vackova M, Smetana J, Lommel P, Kaliskova E, Borys D, Schuerman L. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet. 2009 Oct 17;374(9698):1339-50. doi: 10.1016/S0140-6736(09)61208-3. PubMed 19837254 ↗
  • Schuerman L, Borys D, Hoet B, Forsgren A, Prymula R. Prevention of otitis media: now a reality? Vaccine. 2009 Sep 25;27(42):5748-54. doi: 10.1016/j.vaccine.2009.07.070. Epub 2009 Aug 8. PubMed 19666154 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006 and a completion of Apr 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2006
First posted
Aug 31, 2006
Start
Sep 2006
CompletionActual
Apr 2007
Last update
Mar 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00370318
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 31, 2006
Start date
Sep 2006
Completion
Apr 2007
Last update
Mar 23, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · RIX4414 vaccine · Acetaminophen

Start the discussion